A Federal Court judge has criticised the lack of progress in a major class action brought against Ford Australia, telling the applicant’s barrister to “get his act together”.
A lawyer for the University of Sydney has attacked ObjectiVision for failing to produce any commercial benefits from the glaucoma detection method at the centre of a patent infringement dispute, despite holding exclusive rights to the technology for 11 years.
A judge has signed off on a multi-million dollar settlement in a class action by retirees who claim they lost $27 million with the collapse of property lender Wickham Securities
Expert witnesses were pitted against each other Wednesday at a trial alleging generic makers infringed a patent covering the anti-depressant Lexapro, and Apotex’ consultant took the brunt of it.
The corporate regulator has confirmed it is investigating AMP over its ‘fees for no service’ practice revealed at the Hayne Royal Commission in stunning testimony Treasurer Scott Morrison on Wednesday called “deeply disturbing”.
A judge has dismissed a second defamation case against Fairfax Media brought by an associate of a murdered Sydney businessman, ruling the plaintiff waived his right to sue again after dropping an earlier suit against the publisher for a $75,000 payout.
A judge has dismissed a bid by Geneva Laboratories to add the sole director of a healthcare product distributor as a defendant in a high-stakes case over counterfeit versions of its popular and premium-priced Bio-Oil line of skin-care products.
Two high ranking analysts from S&P Global have distanced themselves from the decision making process at the heart of a class action over toxic financial products given healthy ratings by the agency ahead of the global financial crisis.
A judge has rejected a bid by information services company SAI Global Property to temporarily ban a former sales manager from working for a direct competitor, saying the executive could not have realistically remembered SAI’s list of thousands of clients.
The maker of the anti-depressant Lexapro faced off Monday against Apotex, Aspen Pharma and Sandoz at a court hearing over the rights to make generic versions of the top-selling product, with a barrister for Lundbeck slamming the three companies’ defence that their drugs were different.